RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
119 hedge funds and large institutions have $1.28B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 26 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
68% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $6.87M
28% more funds holding
Funds holding: 93 → 119 (+26)
Holders
119
Holding in Top 10
7
Calls
$11.6M
Puts
$6.87M
Top Buyers
| 1 | +$55.1M | |
| 2 | +$48.5M | |
| 3 | +$45M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.6M |
| 5 |
BlackRock
New York
|
+$34.7M |
Top Sellers
| 1 | -$25.8M | |
| 2 | -$14.2M | |
| 3 | -$7.55M | |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.91M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.93M |